Haleos Labs Limited (HALEOSLABS.BO)
BSE · INR · Healthcare · Biotechnology
₹1,452.00 (+0.00%) as of
Key statistics
- Market cap
- 4.39B
- P/E (TTM)
- 25.89
- EPS (TTM)
- 56.08
- Dividend yield
- 0.10%
- 52-week range
- 1,100.60 – 1,778.35
- Beta
- 0.32
- Revenue (TTM)
- 3.24B
- Profit margin
- 4.87%
- Volume
- 302.00
About Haleos Labs Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also export its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hyderabad, India
- Employees
- 611
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.